報價延遲最少15分鐘:2025/06/01 03:51 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
3.63 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-1.92/-0.33
|
|
企業價值
239.87M
|
| 資產負債 |
|
每股賬面淨值
-0.10
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
36.33M
|
|
每股收益
0.07
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/06/01 03:51 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| scPharmaceuticals Inc is a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce healthcare costs. The company's main product is Furoscix to treat congestion in patients with heart failure and edema in patients with chronic kidney disease. Furoscix is a novel formulation of furosemide contained in a pre-filled, Crystal Zenith cartridge and self-administered subcutaneously via a single-use, disposable, and wearable on-body delivery system. |